Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, has launched in India the first triple-drug fixed-dose combination (FDC) of the widelyused Teneligliptin with Dapagliflozin and Metformin. This FDC has been launched under the brand name Zita DM, and it contains the DPP4 inhibitor, Teneligliptin (20mg), the SGLT2 inhibitor, Dapagliflozin, (10mg), and Metformin SR (500mg/1000mg) in a fixed dose. It must be taken once daily, under prescription, to improve glycemic control in patients with Type 2 diabetes.
Anti-diabetes drugs and patented antivirals to get cheaper, NLEM notified
Glenmark Pharmaceuticals on Thursday said it has launched a fixed-dose combination for the treatment of diabetes for patients with comorbidities. The Mumbai-based drug maker said it has become the first company to launch Teneligliptin (20mg) + Dapagliflozin (5mg/10mg) fixed-dose combination for the treatment of adult patients with type 2 diabetes.
India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.
Prices of several anti-diabetes drugs, patented antivirals used in the treatment of tuberculosis, HIV and hepatitis C are set to get cheaper with their inclusion in the latest edition of National List of Essential Medicines, 2022, released on Tuesday.
Mumbai, April 26, 2022: Glenmark Pharmaceuticals Limited (Glenmark), an innovati ..
Japan based Mitsubishi Tanabe Pharma Corporation (MTPC) has announced that MTPC’s subsidiary in Thailand obtained the regulatory approval of TENELIA® (generic name; teneligliptin hydrobromide hydrate; Japan name: TENELIA® 20mg tablets) for a treatment agent for type 2 diabetes mellitus from Food and Drug Administration Thailand, following the completion of the approval application procedure.
Japan based Mitsubishi Tanabe Pharma Corporation (MTPC) has announced that MTPC’s subsidiary in Thailand obtained the regulatory approval of TENELIA® (generic name; teneligliptin hydrobromide hydrate; Japan name: TENELIA® 20mg tablets) for a treatment agent for type 2 diabetes mellitus from Food and Drug Administration Thailand, following the completion of the approval application procedure.